GenScript expands peptide production capabilities to include neoantigen peptides and APIs
25 Oct 2025
With over 20 years of expertise in custom peptide services, GenScript is a global leader in delivering high-quality peptides for drug discovery and development. The company specializes in neoantigen peptides for personalized therapies, as well as complex modified peptides, including innovative cyclic peptides, peptide conjugates, and other customized peptide formats. Expanding its capabilities, GenScript now offers fast-track cGMP production of neoantigen peptides and peptide active pharmaceutical ingredients (APIs) from its state-of-the-art life sciences manufacturing facility in Zhenjiang, ensuring rapid, reliable, and regulatory-compliant supply for customers worldwide.
About the company
GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions.
